Trial Profile

A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 May 2021 Results of a retrospective analysis of data from studies Bristol Myers Squibb and AbbVie Inc (NCT00858871and NCT01009593) to quantify the rate of tumour progression in patients receiving sorafenib published in the Journal of Hepatology
11 Jun 2019 A Statistical model that allows personalised survival prediction following sorafenib treatment using data from 2 trials (NCT00858871 and NCT00699374) ;results published in the British Journal of Cancer
26 Aug 2013 Results published in the Journal of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com